FindTrial
Sign In

Drugs used for sedation in pediatric ICU

Dexmedetomidine compared with midazolam for sedation of pediatric patients on mechanical ventilation in the intensive care unit : comparative observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/12/029759
Enrollment
60
Registered
2020-12-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J99- Respiratory disorders in diseasesclassified elsewhere Health Condition 2: J99- Respiratory disorders in diseasesclassified elsewhere

Interventions

None listed

Sponsors

Gangula Sindhu Abhinaya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.age group: 2-14yrs 2.all patients having indication for mechanical 3.ventilation ( Invasive and Non invasive ) requiring sedation for more than 24hours

Exclusion criteria

Exclusion criteria: 1.Dexmedetomidine within last 7 days prior to admission 2.Sedation >72hrs prior to screening 3.Cardiac failure or Arterial hypotension 4.Known hypersensitivity to dexmedetomidine, midazolam or any of their formulation ingredients and their rescue medications

Design outcomes

Primary

MeasureTime frame
To assess the sedative properties (efficacy) of continuous intravenous Dexmedetomidine compared with continuous intravenous midazolam in mechanically ventilated children and adolescents (2-14 years) admitted to a PICUTimepoint: 6-8 hours—

Secondary

MeasureTime frame
To evaluate the safety ,cost effectiveness , ICU related delirium of Dexmedetomidine compared with midazolam in ventilated children and adolescents admitted to PICU.Timepoint: 48-72hours—

Countries

India

Contacts

Public ContactGangula Sindhu Abhinaya

Kalinga Institute of Medical Sciences

docreshmis@gmail.com9776999257

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026